We are live on
!
Find out more
Nektar Therapeutics
NKTR
NKTR
215 hedge funds and large institutions have $1.92B invested in Nektar Therapeutics in 2026 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 74 increasing their positions, 48 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
162% more capital invested
Capital invested by funds: $732M → $1.92B (+$1.19B)
160% more funds holding in top 10
Funds holding in top 10: 5 → 13 (+8)
122% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 32
109% more call options, than puts
Call options by funds: $76M | Put options by funds: $36.5M
54% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 48
19% more funds holding
Funds holding: 180 → 215 (+35)
7.93% more ownership
Funds ownership: 85.14% → 93.07% (+7.9%)
Holders
215
Holders Change
+35
Holders Change %
+19.44%
% of All Funds
2.65%
Holding in Top 10
13
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+160%
% of All Funds
0.16%
New
71
Increased
74
Reduced
48
Closed
32
Calls
$76M
Puts
$36.5M
Net Calls
+$39.6M
Net Calls Change
+$29.8M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$239M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
+$69.1M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$56.9M |
| 4 |
Two Sigma Investments
New York
|
+$26.1M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$23.1M |
